Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Challenges of CAR T-cell treatment in pediatric ALL

Christina Peters • 29 Jun 2020
ESH AL 2020
Acute Lymphoblastic Leukemia Leukemia CAR-T Tisagenlecleucel

Christina Peters, MD, St. Anna Children’s Hospital, Vienna, Austria, discusses the drawbacks and challenges that we must overcome in CAR T-cell treatment in pediatric cases of acute lymphoblastic leukemia (ALL). Complications can include inability to collect enough lymphocytes and potential viral infections. In addition, Dr Peters discusses the success rate of the treatment and importance of monitoring the patient’s progress once in remission. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Christina Peters

TBI prior to alloSCT in patients with ALL: the FORUM trials
1:57
TBI prior to alloSCT in patients with ALL: the FORUM trials
Christina Peters • 15 Apr 2024
Barriers that remain in the treatment of pediatric ALL with CAR-T therapies
1:35
Barriers that remain in the treatment of pediatric ALL with CAR-T therapies
Christina Peters • 15 Apr 2024
Optimizing bridging therapy for CAR-T in children and young adults with R/R ALL
2:14
Optimizing bridging therapy for CAR-T in children and young adults with R/R ALL
Christina Peters • 15 Apr 2024
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals